-
公开(公告)号：US20200277361A1
公开(公告)日：2020-09-03
申请号：US16789319
申请日：2020-02-12
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
公开(公告)号：US20200055929A1
公开(公告)日：2020-02-20
申请号：US16669375
申请日：2019-10-30
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
公开(公告)号：US20190071491A1
公开(公告)日：2019-03-07
申请号：US16129618
申请日：2018-09-12
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： Yue Liu , Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
公开(公告)号：US20160257737A1
公开(公告)日：2016-09-08
申请号：US15009667
申请日：2016-01-28
Applicant: Prothena Biosciences Limited , University Health Network
Inventor： Yue Liu , Avijit Chakrabartty , Jeffrey N. Higaki
IPC: C07K16/18
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Abstract translation: 本发明提供了特异性结合转甲状腺素蛋白（TTR）的抗体。 抗体可用于治疗或预防与TTR积累或TTR沉积物积聚（例如，TTR淀粉样变性）相关的疾病或病症。 抗体也可用于诊断TTR淀粉样变性和抑制或减少TTR的聚集，以及其他应用。
-
公开(公告)号：US20170121398A1
公开(公告)日：2017-05-04
申请号：US15201416
申请日：2016-07-02
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/6893 , G01N33/6896 , G01N2800/28 , G01N2800/32
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
Patent Agency Ranking
公开(公告)号：US20160257736A1
公开(公告)日：2016-09-08
申请号：US15009666
申请日：2016-01-28
Applicant: Prothena Biosciences Limited , University Health Network
Inventor： Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
IPC: C07K16/18
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
公开(公告)号：US10464999B2
公开(公告)日：2019-11-05
申请号：US15201423
申请日：2016-07-02
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： Yue Liu , Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
公开(公告)号：US20160251418A1
公开(公告)日：2016-09-01
申请号：US15009662
申请日：2016-01-28
Applicant: Prothena Biosciences Limited , University Health Network
Inventor： Yue Liu , Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
IPC: C07K16/18
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
Abstract: The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
Abstract translation: 本发明提供了特异性结合转甲状腺素蛋白（TTR）的抗体。 抗体可用于治疗或预防与TTR积累或TTR沉积物积聚（例如，TTR淀粉样变性）相关的疾病或病症。 抗体也可用于诊断TTR淀粉样变性和抑制或减少TTR的聚集，以及其他应用。
-
公开(公告)号：US20180201670A1
公开(公告)日：2018-07-19
申请号：US15861600
申请日：2018-01-03
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/6893 , G01N33/6896 , G01N2800/28 , G01N2800/32
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
公开(公告)号：US09879080B2
公开(公告)日：2018-01-30
申请号：US15201416
申请日：2016-07-02
Applicant: PROTHENA BIOSCIENCES LIMITED , UNIVERSITY HEALTH NETWORK
Inventor： Tarlochan S. Nijjar , Avijit Chakrabartty , Jeffrey N. Higaki
CPC classification number: C07K16/18 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , G01N33/6893 , G01N33/6896 , G01N2800/28 , G01N2800/32
Abstract: The invention provides antibodies that specifically bind to transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.027 seconds)
